检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:孙子凯[1] 曹龙兴[2] 李志樑[2] 靳文[2] 傅强[2]
机构地区:[1]南京医科大学附属常州第二人民医院心内科,江苏常州213000 [2]南方医科大学附属珠江医院心内科
出 处:《临床心血管病杂志》2013年第8期590-593,共4页Journal of Clinical Cardiology
基 金:广东省科技计划项目(No:2010B031500030)
摘 要:目的:观察冠状动脉(冠脉)内注射血小板GPⅡb/Ⅲa受体拮抗剂(盐酸替罗非班)对急性冠脉综合征(ACS)患者血栓前状态的影响及临床安全性。方法:77例接受PCI的ACS患者,随机分为A组(予以冠脉替罗非班治疗,38例)、B组(予以静脉替罗非班治疗,39例);测定PCI时病变血管TIMI血流、校正TIMI计帧数(cTFC)以及术后30d心血管事件和出血并发症发生率,观察PCI术前及术后冠状窦血清中血管性血友病因子(vWF)及血小板α-颗粒膜蛋白(GMP-140)水平变化。结果:术后A、B两组PCI后即刻TIMI血流差异无统计学意义,A组cTFC明显低于B组(P<0.05)。两组PCI术后30d心血管事件及出血并发症发生率差异无统计学意义。A组PCI术后即刻冠状窦血清vWF及GMP-140水平较术前显著降低(P<0.05),且A组明显低于B组(P<0.05)。结论:ACS患者PCI时冠脉内注射替罗非班较静脉注射能够更有效地抑制血小板活化,改善血栓前状态。Objective:To evaluate the effect and safety of intracoronary tirofiban on prethromobotic state inpatients with acute coronary syndrome (ACS). Method:Seventy-seven patients with ACS were randomly allocated to receive intracoronary tirofibanin (Group A, n=38) or intravenous tirofibanin (Group B, n=39). TIM/ flow grade, corrected TIMI frame count (cTFC), coronary sinus serum specimen vWF and GMP-140 were determined during the procedure. The 30-day outcome and hemorrhagic complications were also recorded. Result: The cTFC after PCI was significantly lower in Group A than that in Group B. The TIMI grade after PCI had no difference between Group A and B. Serum levels of vWF and GMP-140 in the coronary sinus were significantly reduced in Group A after tirofiban administration (P〈0.05). Compared with Group B, the Serum levels of vWF and GMP-140 were significantly lower in Group A after tirofiban administration (P〈0.05). The 30-day outcome and bleeding complications were similar in both groups. Conclusion:In patients with ACS undergoing primary PCI, intracoronary bolus administration of tirofihan is superior to intravenous bolus injection for depressing the progress of platelet activation and ameliorating the prethrombotic state.
关 键 词:急性冠脉综合征 血栓前状态 GPⅡb Ⅲa受体拮抗剂 替罗非班
分 类 号:R541.4[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:3.129.92.14